← Back to front page
United States · Platforms & data · Yahoo Finance

Actinium Pharmaceuticals Provides Third Quarter 2026 Corporate Update Highlighting ATNM-400 and Other Business Progress

Published by Yahoo Finance · United States 9 h ago
Actinium Pharmaceuticals Logo
Actinium Pharmaceuticals Logo · Yahoo Finance

Detailed summary

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies with the potential to transform cancer treatment, today provided a third quarter 2026 corporate update highlighting recent clinical progress with ATNM-400, initiation of its RADIANZ pan-tumor imaging study, and advancements across its broader pipeline.

NEW YORK, Nov. 17, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies with the potential to transform cancer treatment, today provided a third quarter 2026 corporate update highlighting recent clinical progress with ATNM-400, initiation of its RADIANZ pan-tumor imaging study, and advancements across its broader pipeline. With ATNM-400 now in clinical development for prostate cancer and multiple clinical and scientific milestones anticipated across its portfolio in 2027, Actinium is entering an important period of pipeline advancement.

"With ATNM-400 now in the clinic, we are advancing a differentiated HER3-targeted approach to alpha radiotherapy with the potential to address significant unmet needs in prostate cancer beyond PSMA," said Sandesh Seth, Actinium's Chairman and Chief Executive Officer. "Our encouraging initial clinical findings support continued dose escalation in mCRPC, while RADIANZ represents an important next step in evaluating HER3 targeting across multiple large solid tumor indications. Looking ahead, 2027 is shaping up to be an important year for Actinium, with anticipated clinical data and development milestones across ATNM-400, Actimab-A and Iomab-ACT.

Looking ahead, Actinium expects a steady cadence of clinical data, scientific presentations and development milestones throughout 2027 as it advances ATNM-400 in prostate cancer and evaluates its broader solid tumor potential, alongside continued progress across its hematology pipeline. In addition, Actinium continues to establish in-house manufacturing capabilities to support its clinical programs and expects to be operational by around year-end.

Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The Company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies.

Opening of the article, excerpted from Yahoo Finance. To read the rest, open the article on the publisher's site.

Read the full article on Yahoo Finance Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)

Also worth reading